LINCOLN PHARMACEUTICALS
Lincoln Pharmaceuticals Share Price
Lincoln Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in LINCOLN PHARMACEUTICALS
Start SIPLincoln Pharmaceuticals Investment Rating
-
Master Rating:
-
Lincoln Pharmaceuticals has an operating revenue of Rs. 427.83 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 20% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 125 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 123 | 103 | 120 | 126 | 120 | 78 |
| Operating Expenses Qtr Cr | 107 | 85 | 96 | 97 | 96 | 63 |
| Operating Profit Qtr Cr | 17 | 17 | 23 | 28 | 24 | 14 |
| Depreciation Qtr Cr | 2 | 2 | 2 | 2 | 1 | 1 |
| Interest Qtr Cr | 0 | 1 | 0 | 0 | 0 | 1 |
| Tax Qtr Cr | 6 | 6 | 6 | 7 | 7 | 3 |
| Net Profit Qtr Cr | 15 | 11 | 18 | 23 | 17 | 12 |
Lincoln Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 287.28
- 50 Day
- 291.73
- 100 Day
- 298.64
- 200 Day
- 315.48
- 20 Day
- 288.93
- 50 Day
- 294.06
- 100 Day
- 293.41
- 200 Day
- 315.39
Lincoln Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 279.12 |
| Second Resistance | 282.04 |
| Third Resistance | 284.07 |
| RSI | 43.14 |
| MFI | 51.8 |
| MACD Single Line | -1.86 |
| MACD | -3.21 |
| Support | |
|---|---|
| First Resistance | 274.17 |
| Second Resistance | 272.14 |
| Third Resistance | 269.22 |
Lincoln Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 15,712 | 926,222 | 58.95 |
| Week | 22,729 | 1,422,823 | 62.6 |
| 1 Month | 40,212 | 2,284,061 | 56.8 |
| 6 Month | 46,142 | 2,649,035 | 57.41 |
Lincoln Pharmaceuticals Result Highlights
Lincoln Pharmaceuticals Synopsis
NSE-Medical-Diversified
Lincoln Pharmace is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 472.08 Cr. and Equity Capital is Rs. 20.03 Cr. for the Year ended 31/03/2022. Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288.| Market Cap | 562 |
| Sales | 472 |
| Shares in Float | 1.12 |
| No of funds | 5 |
| Yield | 0.53 |
| Book Value | 1.3 |
| U/D Vol ratio | 1 |
| LTDebt / Equity | |
| Alpha | -0.13 |
| Beta | 0.95 |
Lincoln Pharmaceuticals
| Owner Name | Jun-22 | Mar-22 | Dec-21 | Sep-21 |
|---|---|---|---|---|
| Promoters | 44.08% | 42.05% | 42.08% | |
| Foreign Portfolio Investors | 0.64% | 0.77% | 0.95% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 39.12% | 38.67% | 38.88% | |
| Others | 16.16% | 18.51% | 18.09% |
Lincoln Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Kishor M Shah | Chairman |
| Mr. Mahendra G Patel | Managing Director |
| Mr. Hashmukh I Patel | Whole Time Director |
| Mr. Munjal M Patel | Whole Time Director |
| Mr. Ashish R Patel | Whole Time Director |
| Mr. Arvind G Patel | Director |
| Mr. Rajnikant G Patel | Director |
| Mr. Ishwarlal A Patel | Independent Director |
| Mr. Pirabhai R Suthar | Independent Director |
| Mr. Meha M Patel | Independent Director |
| Mr. Saurin J Parikh | Independent Director |
Lincoln Pharmaceuticals Forecast
Price Estimates
Lincoln Pharmaceuticals Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-08-09 | Quarterly Results | |
| 2022-05-19 | Audited Results & Dividend | |
| 2022-02-10 | Quarterly Results | |
| 2021-11-11 | Quarterly Results | |
| 2021-10-05 | Others | inter-alia, 1) To issue/ allot equity shares to the eligible shareholders of Lincoln Parenteral Ltd. pursuant to Scheme of Amalgamation. per share(15%)Dividend |
Lincoln Pharmaceuticals FAQs
What is Share Price of Lincoln Pharmaceuticals ?
Lincoln Pharmaceuticals share price is ₹281 As on 30 September, 2022 | 02:31
What is the Market Cap of Lincoln Pharmaceuticals ?
The Market Cap of Lincoln Pharmaceuticals is ₹564.6 Cr As on 30 September, 2022 | 02:31
What is the P/E ratio of Lincoln Pharmaceuticals ?
The P/E ratio of Lincoln Pharmaceuticals is 8.5 As on 30 September, 2022 | 02:31
What is the PB ratio of Lincoln Pharmaceuticals ?
The PB ratio of Lincoln Pharmaceuticals is 1.3 As on 30 September, 2022 | 02:31